Taufik Adhi Prasetya Wardana
Taufik Adhi Prasetya Wardana has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Afif Budi Andy B1 shared publication
- Agus Mohamad Soleh
IPB University
1 shared publication - Bagus Sartono
IPB University
1 shared publication - Fitriagustiani Fitriagustiani
Institut Teknologi dan Kesehatan Muhammadiyah Kalimantan Barat
1 shared publication - Kusnaeni Kusnaeni
Institut Teknologi Bacharuddin Jusuf Habibie
1 shared publication - Muhammad Fadhil Nurahmad
Department of Science, Institut Teknologi Bacharuddin Jusuf Habibie, Indonesia
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
A Hybrid ChemBERTa–Morgan XGBoost Ensemble for Computational Multi-Endpoint Toxicity Prioritization of Blumea balsamifera Compounds
Biological investigations of Blumea balsamifera remain dominated by extract or fraction-based testing; consequently, the activities of individual compounds across various biological mechanisms have not been consistently characterized. This study developed a computational framework to prioritize 31 Blumea balsamifera compounds based on their predicted activities across 12 Tox21 endpoints. The framework integrates Morgan fingerprints, RDKit descriptors, and ChemBERTa embeddings through two endpoint-specific XGBoost branches combined using an equal-weight soft voting ensemble of calibrated probabilities. The models were developed using 7,820 Tox21 structures after three structures identical to the target compounds were excluded. Evaluation was performed using repeated five-fold scaffold cross-validation, Platt scaling, endpoint-specific thresholds, and applicability domain analysis. The ensemble achieved mean ROC-AUC, average precision, balanced accuracy, and MCC values of 0.784±0.063, 0.372±0.130, 0.712±0.052, and 0.273±0.103, respectively. Luteolin-7-methyl-ether ranked highest, with a score of 37.10 and predicted activity at 11 endpoints. This framework supports the selection of compounds for more targeted biological validation.• Develops a hybrid framework for computational prioritization of toxicity-related activity across 12 Tox21 endpoints.• Integrates Morgan fingerprints, RDKit descriptors, and ChemBERTa embeddings into a calibrated XGBoost ensemble.• Identifies luteolin-7-methyl ether as the highest priority candidate for multi-endpoint biological validation.
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Hybrid ChemBERTa–Morgan XGBoost Ensemble for Computational Multi-Endpoint Toxicity Prioritization of Blumea balsamifera Compounds
Biological investigations of Blumea balsamifera remain dominated by extract or fraction-based testing; consequently, the activities of individual compounds across various biological mechanisms have not been consistently characterized. This study developed a computational framework to prioritize 31 Blumea balsamifera compounds based on their predicted activities across 12 Tox21 endpoints. The framework integrates Morgan fingerprints, RDKit descriptors, and ChemBERTa embeddings through two endpoint-specific XGBoost branches combined using an equal-weight soft voting ensemble of calibrated probabilities. The models were developed using 7,820 Tox21 structures after three structures identical to the target compounds were excluded. Evaluation was performed using repeated five-fold scaffold cross-validation, Platt scaling, endpoint-specific thresholds, and applicability domain analysis. The ensemble achieved mean ROC-AUC, average precision, balanced accuracy, and MCC values of 0.784±0.063, 0.372±0.130, 0.712±0.052, and 0.273±0.103, respectively. Luteolin-7-methyl-ether ranked highest, with a score of 37.10 and predicted activity at 11 endpoints. This framework supports the selection of compounds for more targeted biological validation.• Develops a hybrid framework for computational prioritization of toxicity-related activity across 12 Tox21 endpoints.• Integrates Morgan fingerprints, RDKit descriptors, and ChemBERTa embeddings into a calibrated XGBoost ensemble.• Identifies luteolin-7-methyl ether as the highest priority candidate for multi-endpoint biological validation.